Roche secures rights to Alector's Parkinson's therapy for up to $1.27 billions, Alector shares surge
路透社2026/10/05 12:16Reuters, October 5 – U.S. biotechnology company Alector announced on Monday that Swiss pharmaceutical giant Roche will pay up to 1.27 billion dollars to obtain licensing rights for its experimental Parkinson's disease therapy. Boosted by this news, Alector’s shares surged 72% in pre-market trading. Genentech, a subsidiary of Roche, will pay Alector a 100 million dollar upfront payment, with an additional payment of up to 1.17 billion dollars if the therapy meets certain developmental, regulatory, and sales milestones. Alector will also receive royalty payments. Specific details are as follows: the agreement grants Genentech exclusive global rights to develop, produce, and commercialize AL050, an experimental therapy targeting enzyme deficiency associated with Parkinson’s disease. Genentech will be responsible for the development, regulatory filings, production, and commercialization of the therapy. AL050 is an enzyme replacement therapy designed to address GCase enzyme deficiency—which leads to the buildup of certain fats and increases the risk of Parkinson’s. This deal is the latest in a series of licensing agreements Roche has reached to expand its drug development pipeline. In June, Roche and Nurix Therapeutics entered into a licensing and collaboration agreement involving a blood cancer medication, with a deal value of up to 2.3 billion dollars.
Reuters, October 5 - US biotechnology company Alector announced on Monday that Swiss pharmaceutical company Roche ROPC.S will pay up to $1.27 billion to acquire the rights to its experimental Parkinson's disease therapy ALEC.O, boosting the company's share price by 72% in pre-market trading.
Roche's subsidiary Genentech will pay Alector an upfront payment of $100 million, and if the therapy meets research, regulatory, and sales targets, an additional payment of up to $1.17 billion will be made. Alector will also receive royalty payments.
Details are as follows:
The agreement grants Genentech exclusive global rights to develop, manufacture, and sell AL050, an experimental therapy aimed at addressing enzyme deficiency associated with Parkinson's disease.
Genentech will be responsible for the development, regulatory filings, manufacturing, and commercialization of the therapy.
AL050 is an enzyme replacement therapy designed to address GCase enzyme deficiency — this deficiency can lead to the accumulation of certain fats and increase the risk of Parkinson's disease.
This transaction is the latest in a series of licensing agreements Roche has reached to expand its drug development pipeline.
In June this year, Roche and Nurix Therapeutics NRIX.O entered into a licensing and collaboration agreement (link) involving a blood cancer drug, with a transaction value of up to $2.3 billion.
(For the convenience of non-native English speakers, Reuters has automated the translation of its reports into several other languages. Because automated translations may contain errors or lack the necessary context, Reuters does not guarantee the accuracy of the automated translation text, and provides it solely for the convenience of readers. Reuters assumes no responsibility for any damages or losses resulting from the use of the automated translation feature.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Will the 30-year yield break 6% this month? Economic resilience and inflation pressures drive rates higher, further intensifying the sell-off in US Treasury bonds
U.S. Treasury bonds faced another round of sell-offs on Monday, pushing long-term yields to their highest levels in decades.
Strive CEO Says ASST Can Outrun Strategy in the Next Bitcoin Bull Market
Allegion Buys Overly Door Company
05:37 PM EDT, 10/05/2026 (MT Newswires) -- Allegion (ALLE) said late Monday it has acquired privately held Overly Door Company, a manufacturer of custom specialty doors for acoustic, blast, bullet-resistant and vault security. Overly, based in Greensburg, Pennsylvania, will operate as part of the Allegion Americas segment, it said. Terms of the transaction weren't disclosed.
Updated Version 3 - According to the Financial Times, McKesson and CD&R are close to reaching a deal worth more than $5 billion to acquire Option Care.
In the fifth paragraph, a quote from analyst Sahil Pandey was added. Reuters, October 5 - According to the Financial Times, citing informed sources, pharmaceutical distributor McKesson (MCK.N) and private equity firm Clayton Dubilier & Rice are about to reach an acquisition agreement to purchase infusion service provider Option Care Health, with the deal valued (including debt) at over 5 billions USD. After the report was published, Option Care's share price rose by 21% in after-hours trading. The report stated that the deal could be announced as early as Tuesday, but negotiations could still fall through. This potential acquisition would be McKesson’s latest move in expanding its healthcare services portfolio. In August this year, the company agreed to acquire Precision Medicine Group for about 2.25 billions USD (link), as part of its effort over the years to strengthen high-growth business sectors. Leerink Partners analyst Michael Cherny said the “strategic logic” of the deal makes sense, as it would expand McKesson’s business from physician offices to care settings in the home and alternative sites. Option Care provides infusion services that allow patients to receive intravenous treatments at home or other outpatient settings, eliminating the need to go to the hospital. McKesson has previously been restructuring its business portfolio by divesting non-core assets and investing in fields such as oncology and specialty care (link). Driven by the growth of its specialty distribution business and contributions from acquisitions, revenue for its oncology and multi-specialty business segment grew by 33% in the latest fiscal quarter. McKesson declined to comment, while CD&R and Option Care did not immediately respond to Reuters’ requests for comment regarding the report. (For non-English speakers' convenience, Reuters offers automated machine translations of its reports in several languages. As there may be mistakes in the automated translations or some context may not be included, Reuters does not guarantee the accuracy of the automated translation text, which is provided solely for readers’ convenience. Reuters bears no responsibility for any damages or losses caused by the use of automated translation functions.)
Crypto prices
More
